Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 August 2021 | Story Leonie Bolleurs | Photo Supplied
Prof Maryke Labuschagne, a successful scientist who is doing great work to enhance food security on the African continent, admires women who have made an impact, often in male-dominated environments.

Maryke Labuschagne, Professor in Plant Breeding at the University of the Free State (UFS), is known to many for her work to enhance food security. 

She holds the National Research Foundation’s South African Research Chairs Initiative (SARChI) Chair on Disease Resistance and Quality in Field Crops, travelling all over Africa to do research on the genetic improvement of staple food crops in communities. Through decades of research and collaboration, she has also contributed to the establishment of a strong network of researchers on the continent.

During an interview in celebration of Women’s Month, Prof Labuschagne talks about her experiences as a young scientist and how she believes young female researchers should be supported and nurtured. 

Is there a woman who inspires you and who you would like to celebrate this Women’s Month, and why?

Besides the scientists she had the opportunity to work with in countries such as Zimbabwe, Zambia, Uganda, Ghana, Ethiopia, Kenya, Lesotho, Eswatini, Tunisia, and Ethiopia, she also met women who are working the fields to produce crops for their families, raising their children, and living in difficult conditions. “These women, who make it work against all odds, inspire me,” says Prof Labuschagne.

Other women she admires and who have made an impact – often in male-dominated environments – include role models from the past, such as former UK prime minister, Margaret Thatcher; physicist Marie Curie, who was far ahead of her time; and American geneticist Barbara McClintock, who won a Nobel Prize in 1983. 

What is your response to current challenges faced by women and available platforms for women development?
 
“When I started working in the Faculty of Natural and Agricultural Sciences at the UFS in 1989, it was a different world. It was a totally (white) male-dominated environment. The number of women scientists could be counted on the fingers of one hand, and they were often not given the same opportunities as their male counterparts,” she recalls.

Prof Labuschagne continues: “With women having so many opportunities today, it is now totally different.”

She believes women will always have a double burden – being responsible for a family and having to compete on an equal footing with male colleagues in the workplace. There are now, however, many platforms and support systems specifically for women, and she encourages women to make use of every available form of assistance they can get.

I would say you can have it all. Work hard, believe in yourself, follow your dreams, focus on your goals, see the opportunities – not the challenges, and leave a legacy. – Prof Maryke Labuschagne
 
What advice would you give to the 15-year-old you?

“I would say you can have it all. Work hard, believe in yourself, follow your dreams, focus on your goals, see the opportunities – not the challenges, and leave a legacy.”

She is convinced that young women can have a family and a career, even if they believe it is not possible. 
 
What would you say makes women of quality, impact, and care?
 
“I see many women at the UFS making their mark, making an impact in their chosen fields.”

According to Prof Labuschagne, what would have been unthinkable just a few decades ago, such as women serving as deans and in top management positions, is now a reality. 

“I see young female researchers boldly taking on the world, believing in themselves and their abilities, and knowing they will be successful.” She states that each of these women should be supported and nurtured, as they will have a huge influence on the course of the university’s future.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept